1Kuerer HM,Newman LA,Smith TL,et al.Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy[J].J Clin Oncol,1999,17(2):460-469.
2Chollet P,Amat S,Cure H,et al.Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer[J].Br J Cancer,2002,86(7)1041-1046.
5Sahoo S,Lester SC.Pathology of breast carcinomas after neoadjuvant chemotherapy:an overview with recommendations on specimen processing and reporting[J].Arch Pathol Lab Med,2009,133(4):633-642.
6Pinder SE,Provenzano E,Earl H,et al.Laboratory handling and histology reporting of breast specimens from patients who have received neoadjuvant chemotherapy[J].Histopathology,2007,50(4):409-417.
7Rabban J.The new edition(7th)AJCC staging system for breast cancer.A summary of key changes[EB/OL],(2010-06)[2015-02-09].http://labmed.ucsf.edu/uploads/210/101_new_ajcc_ staging_of_breast_cancer_what_has_changed.pdf.
8Edge S,Byrd D,Compton C,et al.AJCC cancer staging manual[M].New York:Springer,2010.
9Schnitt SJ,Collins LC.Biopsy interpretation of the breast[M].Philadelphia:Lippincott Williams & Wilkins,2009:435-439.
10Lakhani SR,Ellis 10,Schnitt SJ,et al.WHO classification of tumours of the breast[M].Lyon:IARC Press,2012.
2Bonadonna G. Evolving concepts in the systemic adjuvant treatment of breast cancer. Cancer Res, 1992, 52 ( 8 ) : 2127- 2137.
3Bear HD, Aderson S, Smith RE,et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol, 2006, 24( 13): 2019-202%
4Ogston KN, Miller ID, Payne S, et al. A new histological grading system to assess response of breast cancers to primary chemotherapy : prognostic significance and survival. Breast, 2003, 12(5) : 320-327.
5Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol, 2007, 25(28) : 4414-4422.
6Estévez LG,Gradishar WJ.Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.Clin Cancer Res,2004,10(10):3249-3261.
7Fisher B,Brown A,Mamounas E,at al.Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer:findings from National Surgical Adjuvant Breast and Bowel Project B-18.J Clin Oncol,1997,15(7):2483-2493.
8Fisher B,Bryant J,Wolmark N,et al.Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.J Clin Oncol,1998,16(8):2672-2685.
9Kimmick GG,Cirrincione C,Duggan DB,et al.Fifteen-year median follow-up results after neoadjuvant doxorubiein,followed by mastectomy,followed by adjuvant cyclophosphamide,methotrexate,and fluorouracil(CMF)followed by radiation for stage Ⅲ breast cancer:a phase Ⅱ trial(CALGB 8944).Breast Cancer Res Treat,2009,113(3):479-490.
10Cariati M,Purushotham AD.Stem cells and breast cancer.Histopathology,2008,52(1):99-107.
